Clarity Science to Present Drug-Free Patch Research at Seven Meetings in Q4 2026

Clarity Science will present data on drug-free haptic patch technology at seven scientific meetings across Europe, North America and Asia in the fourth quarter of 2026. The presentations build on placebo-controlled studies in sleep, pain, balance, stress, anxiety and athletic performance, including a Best Abstract award at Business of Pain 2026.

Why it matters: - Clarity Science is bringing data on a drug-free wearable technology to seven scientific meetings in one quarter. - The presentations could broaden interest in non-pharmacological approaches for sleep, pain, balance, stress, anxiety and athletic performance. - The pain research already won Best Abstract at Business of Pain 2026, giving the program added visibility.

What happened: - Clarity Science, a contract research organization based in Narragansett, Rhode Island, was invited to present research on Haptic Vibrotactile Transduction/Trigger Technology at seven scientific meetings in Europe, North America and Asia in Q4 2026. - Peter Hurwitz, president of Clarity Science, and Jeffrey Gudin, MD, of the University of Miami Miller School of Medicine will present the data. - The presentations combine results from multiple randomized, placebo-controlled studies of wearable haptic patches made by The Super Patch Company. - The pain program was named Best Abstract at Business of Pain 2026 in Miami Beach, Florida, held Oct. 8-11, 2026. - The award-winning pain study found that a haptic patch reduced pain severity and interference and improved range of motion compared with placebo in a randomized, double-blind study of 118 adults.

The details: - Recent presentations included Business of Pain 2026 in Miami Beach and the 39th ECNP Congress in Munich, Germany. - Upcoming presentations include ANA 2026 in San Diego, ESRS 2026 in Maastricht, icSPORTS 2026 in Angers, IASP 2026 World Congress on Pain in Bangkok and Neuroscience 2026 in Washington, D.C. - The RESTORE sleep trial of the REM Patch reported 79% lower Insomnia Severity Index scores and 76% lower Pittsburgh Sleep Quality Index scores by Day 14 versus baseline, with results significantly better than placebo (p<0.001). - The RESTORE pain trial of the FREEDOM Patch showed significantly greater reductions in pain severity and interference than placebo, along with improved range of motion. - The PROTECT trial of the LIBERTY Patch reported fewer participants in a “high-risk” fall classification and significant improvements in reaction time and time to stand and sit (p<0.05). - The STRAVA trial of the PEACE Patch found a 33% drop in Perceived Stress Scale scores by Day 14, moving participants from moderate to low stress, with significant reductions in anxiety and depressive symptoms (p<0.001). - The POWER-UP trial of the VICTORY Patch in NCAA Division I athletes found knee strength increased by up to 8% from baseline and left-right strength imbalance declined significantly (p=0.026). - The technology is designed to stimulate mechanoreceptors in the skin. - Investigators propose that the resulting signal engages PIEZO1 and PIEZO2 mechanosensitive ion channels, which carry sensory information through the peripheral nervous system to the brain. - Researchers say that one sensory pathway may help explain why the technology appears to affect several different health outcomes. - The studies were funded by SRYSTY Holding Co. / The Super Patch Company and were conducted by Clarity Science and collaborating sites under independent IRB oversight. - Clarity Science says its studies are conducted with academic and clinical collaborators and have been published in peer-reviewed journals. - The Super Patch Company is a privately held wellness technology company based in Toronto that develops drug-free, non-invasive wearable patches incorporating VTT. - The Super Patch Company website is More information. - Study sources cited in the release include a 2025 narrative review in Cureus, a 2025 pain study in Pain and Therapy, and the POWER-UP trial indexed on PubMed.

Between the lines: - The quarter-long conference run suggests the company is trying to position the technology across multiple medical and performance categories, not just pain. - The mix of neurology, sleep, neuroscience and sport-science meetings points to a broader commercialization and credibility push. - The mechanistic explanation remains a proposed pathway, while the clinical claims rest on placebo-controlled study results.

What's next: - Clarity Science will continue presenting the dataset at the remaining Q4 2026 conferences. - The broader scientific reception at those meetings will help determine whether the patches gain more attention in clinical and performance research circles. - Peter Hurwitz is the media contact for Clarity Science in Narragansett, Rhode Island.

The bottom line: - Clarity Science is using a high-profile conference circuit to advance evidence for a drug-free haptic patch platform that it says has shown measurable effects across sleep, pain, balance, stress and athletic performance.